EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Oncogenic KRAS Using Peptide Nucleic Acid Oligomers Attached to Cell-Penetrating Peptides

Jayati Mondal, Dennis Lam iD, Termika O Alcindor, Mary E Gerritsen, Tilmann M Brotz iD, Jodi Kennedy, Bruce Rehlaender, Arthur J Ross, Daniel E Levy, Christopher A Bonagura, William N Lanzilotta, Frank McCormick und 2 weitere

International Journal of Molecular Sciences · 10.08.2026 · 27 (16) · 7158

DOI: 10.3390/ijms27167158 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 10.08.2026. Verfasst von Jayati Mondal und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Hunter College, City University of New York, New York, NY 10065, USA. Hauptthemen laut MEDLINE: Peptide Nucleic Acids, Cell-Penetrating Peptides, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, PSC-CUNY, Oncogenuity, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Approximately 30% of tumors contain an activating mutation in the oncogene KRAS, leading to increased cell proliferation that often promotes non-small cell lung cancers, colorectal adenocarcinomas, pancreatic ductal adenocarcinomas (PDAC), and other cancers. Among the most common point mutations in KRAS is G12D, an example of an oncogenic sequence present in tumor cells but not normal cells. We developed peptide nucleic acid (PNA) oligomers that selectively bind KRAS G12D sequences and fused them with novel cell-penetrating peptide flanking regions (CPP-PNA-G12D) then evaluated them. Electrophoretic mobility shift assays demonstrated in vitro binding to and selectivity for KRAS G12D over wild-type KRAS and KRAS G12C. Cells and nuclei were able to uptake CPP-PNA-G12D at high efficiency as shown by fluorescent microscopy and flow cytometry. Cell viability assays showed a striking dose-response effect in on-target cells expressing KRAS G12D, while relatively sparing off-target cells expressing KRAS G12C. CPP-PNA-G12D constructs were effective against a panel of PDAC cell lines and in female Balb/c mice bearing patient-derived xenografts. These results show promise for an enhanced PNA-delivery peptide conjugate strategy as a potential therapeutic strategy to selectively target KRAS mutant cancer cells, with the potential to expand this technology to additional cancer-derived mutant oncogenes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peptide Nucleic AcidsCell-Penetrating PeptidesProto-Oncogene Proteins p21(ras)HumansAnimalsFemaleMiceCell Line, TumorMice, Inbred BALB CPancreatic NeoplasmsXenograft Model Antitumor Assays

Stichwörter der Autor:innen

CPPG12DKRASNSCLCPDACPNAcell-penetrating peptideinhibitionlung cancermutantpancreatic cancerpeptide nucleic acidtherapy

Substanzen

Peptide Nucleic AcidsCell-Penetrating PeptidesProto-Oncogene Proteins p21(ras)KRAS protein, human

Autor:innen und Institutionen

  • Department of Biological Sciences, Hunter College, City University of New York, New York, NY 10065, USA.
  • Yalow Scholars Program, Hunter College, City University of New York, New York, NY 10065, USA.
  • Damon Runyon Cancer Research Foundation, Scholars Program for Advancing Research and Knowledge, New York, NY 10006, USA.
  • Maximizing Access to Research Careers Program, Hunter College, City University of New York, New York, NY 10065, USA.
  • McNulty Scholars Program, Hunter College, City University of New York, New York, NY 10065, USA.
  • Transfer to STEM Student Success Program, Hunter College, City University of New York, New York, NY 10065, USA.

ORCID-Profile: Dennis Lam, Tilmann M Brotz, Andrew L Wolfe

Förderung

  • NCI NIH HHS
  • PSC-CUNY
  • Oncogenuity, Inc.
  • NIGMS NIH HHS
  • U.S. National Science Foundation
  • NIMHD NIH HHS
  • CUNY Transfer to STEM Student Success
  • Hunter College

Zitieren

APA

Mondal, J., Lam, D., Alcindor, T. O., Gerritsen, M. E., Brotz, T. M., Kennedy, J., Rehlaender, B., Ross, A. J., Levy, D. E., Bonagura, C. A., Lanzilotta, W. N., McCormick, F., Rothman, J. H., & Wolfe, A. L. (2026). Targeting Oncogenic KRAS Using Peptide Nucleic Acid Oligomers Attached to Cell-Penetrating Peptides. International Journal of Molecular Sciences, 27(16), 7158. https://doi.org/10.3390/ijms27167158

Vancouver

Mondal J, Lam D, Alcindor TO, Gerritsen ME, Brotz TM, Kennedy J, et al. Targeting Oncogenic KRAS Using Peptide Nucleic Acid Oligomers Attached to Cell-Penetrating Peptides. International Journal of Molecular Sciences. 2026;27(16):7158. doi:10.3390/ijms27167158

BibTeX
@article{Mondal2026,
  author = {Mondal, Jayati and Lam, Dennis and Alcindor, Termika O and Gerritsen, Mary E and Brotz, Tilmann M and Kennedy, Jodi and Rehlaender, Bruce and Ross, Arthur J and Levy, Daniel E and Bonagura, Christopher A and Lanzilotta, William N and McCormick, Frank and Rothman, Jeffrey H and Wolfe, Andrew L},
  title = {Targeting Oncogenic KRAS Using Peptide Nucleic Acid Oligomers Attached to Cell-Penetrating Peptides},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {16},
  pages = {7158},
  doi = {10.3390/ijms27167158}
}
Kostenlos starten →